These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38766421)

  • 41. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.
    Younossi ZM; Stepanova M; Al Shabeeb R; Eberly KE; Shah D; Nguyen V; Ong J; Henry L; Alqahtani SA
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Siddiqui MS; Muthiah M; Satapathy SK; Patidar KR; Bhat M; Brandman D; Watt KD; Rinella M
    Hepatology; 2023 Dec; ():. PubMed ID: 38088872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Vaz J; Jepsen P; Strömberg U; Midlöv P; Eriksson B; Buchebner D; Hagström H
    Int J Cancer; 2024 Jul; ():. PubMed ID: 39016032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
    Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.
    Ossima AN; Brzustowski A; Paradis V; Van Beers B; Postic C; Laouénan C; Pol S; Castéra L; Gautier JF; Czernichow S; Vallet-Pichard A; Larger E; Serfaty L; Zins M; Valla D; Zaleski ID
    Clin Diabetes Endocrinol; 2024 Apr; 10(1):9. PubMed ID: 38659082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
    Etzion O; Bareket-Samish A; Yardeni D; Fishman P
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research.
    Ramirez AG; Weiss NS; Holden AE; Suarez L; Cooper SP; Munoz E; Naylor SL
    PLoS One; 2012; 7(4):e35573. PubMed ID: 22530052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease.
    Ragheb M; Grubert Van Iderstine M; Minuk G; Faisal N
    Can Liver J; 2024 May; 7(2):291-298. PubMed ID: 38746864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review.
    Ha J; Chaudhri A; Avirineni A; Pan JJ
    Biomark Res; 2017; 5():15. PubMed ID: 28439416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
    Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
    Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
    Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Hepatocellular Carcinoma in Hispanic and Non-Hispanic Patients.
    Asemota J; Oladunjoye O; Babalola A; Nwosu U; Liu PS; Oladunjoye AO; Castro-Webb N; Miksad RA
    Cureus; 2021 May; 13(5):e14884. PubMed ID: 34104609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
    Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
    JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States.
    Sohail A; Ali H; Patel P; Subramanium S; Dahiya DS; Sohail AH; Gangwani MK; Satapathy SK
    World J Virol; 2024 Mar; 13(1):91149. PubMed ID: 38616849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.
    Eskridge W; Cryer DR; Schattenberg JM; Gastaldelli A; Malhi H; Allen AM; Noureddin M; Sanyal AJ
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.